Unknown

Dataset Information

0

Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.


ABSTRACT: HIV persistence despite therapy contributes to chronic immune activation and inflammation, increasing the risk of aging-associated events in HIV-infected individuals. We sought here to better understand the complex link between clinical and treatment features and HIV persistence despite therapy. A total of 11,045 samples from 1,160 individuals under combination antiretroviral therapy (cART) with an unquantifiable viral load (VL; limit of quantification, 20 copies/ml) were categorized as detectable or undetectable depending on the detection of a PCR signal using a commercially available assay. Generalized estimating equation (GEE) regression was used to model viral load detectability and to assess the determinants of residual viremia (RV; VL detected below 20 copies/ml) despite therapy. A high VL zenith was associated with a higher probability to have a detectable viremia under cART. Conversely, the probability to have a detectable viral load below 20 copies/ml decreased with time under therapy. Of therapy regimens, protease inhibitor (PI)-based cART was associated with a significantly higher probability of detectable RV compared to nonnucleoside transcriptase inhibitor- or integrase inhibitor-based cART. We found that a PI-based treatment regimen is highly associated with an increased frequency of RV, supporting previous evidence suggesting that PI-based cART regimens could favor ongoing viral replication in some individuals.

SUBMITTER: Darcis G 

PROVIDER: S-EPMC7038286 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.

Darcis Gilles G   Maes Nathalie N   Pasternak Alexander O AO   Sauvage Anne-Sophie AS   Frippiat Frédéric F   Meuris Christelle C   Uurlings Françoise F   Lecomte Marianne M   Léonard Philippe P   Elmoussaoui Majdouline M   Fombellida Karine K   Vaira Dolores D   Moutschen Michel M  

Antimicrobial agents and chemotherapy 20200221 3


HIV persistence despite therapy contributes to chronic immune activation and inflammation, increasing the risk of aging-associated events in HIV-infected individuals. We sought here to better understand the complex link between clinical and treatment features and HIV persistence despite therapy. A total of 11,045 samples from 1,160 individuals under combination antiretroviral therapy (cART) with an unquantifiable viral load (VL; limit of quantification, 20 copies/ml) were categorized as detectab  ...[more]

Similar Datasets

| S-EPMC2685743 | biostudies-literature
| S-EPMC2765414 | biostudies-literature
| S-EPMC3139616 | biostudies-literature
| S-EPMC7685884 | biostudies-literature
| S-EPMC7473585 | biostudies-literature
| S-EPMC8460250 | biostudies-literature
| S-EPMC4721905 | biostudies-literature
| S-EPMC8042152 | biostudies-literature
| S-EPMC7173622 | biostudies-literature
| S-EPMC2795168 | biostudies-literature